 |
Span Diagnostics | Span
Diagnostics
clocked
an estimated revenue of  92.53 crore for FY
2010-2011, as against 78.98 crore for 2009-10. The company,
which has
been supplying to India’s national programmes for AIDS and malaria
since the past eight years, achieved tender sales worth 28 crore from
the Indian government during the past year. Span currently houses three
businesses namely, the diagnostic reagent business, the instruments
business and exports, and boasts of a joint venture with Japan-based,
Nihon Kohden corporation. The company is looking to modernize its plant
by investing 12 crore over a period of one-and-half
years. The company
expects to grow at a rate of 17 to 20 percent in 2011, following which,
Span anticipates hitting a growth rate of 25 to 30 percent. This
confidence is due to the launch of a number of products by 2012 along
with an increase in export sales. Span is looking to achieve a turnover
of 1,000 crore by 2020. |
| Founder
and
Chairman Dr Pradip Desai |
||
|
36
|
Business: Provider of diagnostic, instruments & clinical chemistry products | |
| Start-up Year: 1976 | ||
| Address: 173- B ,New industrial
Estate, Udhna, Surat – 394210, Gujarat |
||
| Tel: +91-261-2277211 Fax: +91-261-2279319, 2665757 Website: www.span.co.in |
||
| Revenue: 92.53
crore* |
||
 |
Aventis Pharma | Aventis
Pharma
clocked
an estimated sales of 90 crore in FY 2010-11 when
compared with 68.34 crore in FY 2009-10. The company
has consolidated
its position in the growing insulin market with its star product
Lantus, which has a market share of 10.24 percent, showing a growth of
nearly 30 percent. Other insulin brands including Amaryl and Apidra
witnessed a growth of 29 percent and 100 percent respectively. During
the FY, the company sold off its entire shareholding in the joint
venture company, Chiron Behring Vaccines Private to Novartis Pharma for
100.7 crore. The company reduced the
price for its monocomponent
insulin, Lantus, by 2.8 percent as per the direction from the National
Pharmaceutical Pricing Authority (NPPA) from 2,439.27 for a 10 ml vial
of Lantus 100 IU/ml to 2,370.49. The company also has several
community service initiatives like the SOS Children’s villages,
Childline, the Akansha Foundation, Voluntary Health Association of Goa
and the Joy of Giving. |
| MD Dr Shailesh Ayyangar |
||
|
37
|
Business: Marketing of biotech products | |
| Start-up Year: 1956 | ||
| Address:
Aventis House, 54/A, Sir Mathuradas, Vasanji Road, Andheri East,
Mumbai-400093 |
||
| Tel: +91-22-28278000 Fax: +91-22-28370939 Website: www.aventispharmaindia.com |
||
| Revenue: 90
crore* |
||
 |
Novartis Vaccines | In
the
FY
2010-2011, the vaccine business of Novartis in India clocked
89.65 crore. In India, Novartis and
Aventis Pharma had a 51:49 joint
venture in Chiron Behring Vaccines, in which the former had marketing
rights of the later’s anti-rabies vaccine, Rabipur, in India. However in December 2010, Aventis Pharma sold off its 49 percent stake in the joint venture to Novartis Vaccines and Diagnostics (NV&D) for around 100 crore. Novartis Vaccines and
Diagnostics division ’s portfolio includes some prominent influenza and
meningitis vaccines and travel vaccines. In the first half of 2010, the division globally completed the distribution of A(H1N1) vaccine. Now, work has started for developing pre-pandemic vaccines that would provide protection to the global population against possible future pandemics. |
| Country
Head,
India Mr Masood Alam |
||
|
38
|
Business: Healthcare, vaccines and diagnostics | |
| Start-up
Year: 2006 |
||
| Address: Novartis India Limited,
Sandoz House, 8th floor, Shivsagar Estate, Dr Annie Besant Road, Worli,
Mumbai - 400 018, India |
||
| Tel: +91-22-24958804, 24951074 Fax: +91-22-2495 2624 Website: www.novartis.in |
||
| Revenue: 89.65
crore* |
||
 |
Ajeet Seeds | Ajeet
Seeds,
a
producer and processor of hybrid cottonseeds in India,
generated a revenue of 87.5 crore in 2010-11. The company
received
approval from the Genetic Engineering Approval Committee (GEAC),
Government of India, for the sale of Bollgard I (Ajeet 33, Ajeet 155,
Ajeet 177), Ajeet 901 (HxB), ACH 21 (Arya 21 Bt) and Bollgard II
(Ajeet-11, Ajeet 155, Ajeet 33), ACH 177 (Arya 177 BG II, Ajeet 111),
ACH 5 (Arya 21 BG II) cotton hybrids in Central, South and North zones
in 2006. The company has developed its own genetic resources of hybrid seeds in cotton, jowar, bajra, maize, chilli, okra and pigeon pea. The company has established a wide network of 400 distributors, 3,000 dealers and more than 30,000 seed growers all over India. The company is gearing up to launch its indigenous transgenics in okra & cotton that would offer resistance to biotic and abiotic stress. |
| MD Mr Sameer Mulay |
||
|
39
|
Business: Research, production, processing and marketing of hybrid seeds | |
| Start-up Year: 1986 | ||
| Address: Tapadia Terraces, 2nd
Floor, Adalat Rd, Aurangabad- 43100 |
||
| Tel: +91-240-2333933 Fax: +91-240-2333335 Website: www.ajeetseed.co.in |
||
| Revenue: 87.5
crore* |
||
 |
Haffkine Bio-Pharmaceutical Corporation | Haffkine
Bio-Pharmaceutical
Corporation
(HBPCL) is engaged in the manufacture
and supply of a wide range of products comprising bacterial and viral
vaccines, antisera, toxoids injectables, disinfectants, ointments,
injectables, syrups and mixtures. The firm clocked an annual sales
revenue of 86 crore for 2010-11 against last year’s 168.98 crore. The
firm’s total group turnover, comprising Haffkine Ajintha
Pharmaceuticals and Antitoxin and Sera is over 100 crore. The
Antitoxin and Sera (ATS) department of HBPCL is located at Pimpri, near
Pune, and it is engaged in the manufacture of antiserum against
tetanus, diphtheria, gas gangrene, snake and scorpion venoms. The ATS
operates on 75 acres of land with a total strength of 400 equines.
HBPCL has supplied oral polio vaccines to UNICEF and the Government of
India. The company is also planning to build manufacturing facilities
complying with the WHO’s GMP standards for DTP/pentavalent vaccine. |
| MD Mr P R Sabde |
||
|
40
|
Business: Production and supply of biopharmaceutical products | |
| Start-up Year: 1975 | ||
| Address:
Acharya Donde Marg, Parel, Mumbai - 400012 |
||
| Tel: +91-22-24129320 Fax: +91-22-24168578 Website: www.vaccinehaffkine.org |
||
| Revenue: 86
crore |
||
